Rezolute Prices $100 Million Offering At $3.87 To Fund Ersodetug Launch Preparation
New common shares account for about 19% of post-offering shares as the company prepares for regulatory discussions.
Rezolute, which develops treatments for dangerously low blood sugar linked to excess insulin activity, priced a $100 million offering Friday at $3.87 per common share. The stock-and-pre-funded-warrant deal prices shares about 5% below Wednesday's $4.07 reference, with new common shares accounting for about 19% of the post-offering total, according to its prospectus supplement filed Monday.
$94 Million Before Expenses
Rezolute would receive $94 million after underwriting discounts and commissions, before expenses. It plans to combine the proceeds with existing cash to fund "ersodetug commercialization preparation and for working capital and general corporate purposes," according to the use-of-proceeds statement.
The deal includes 22,040,976 common shares and pre-funded warrants covering up to 3,800,000 additional shares. The stated post-offering common-share count of 118,763,309 excludes those warrant shares.
Morgan Stanley, Guggenheim Securities and Cantor are the joint book-running managers. H.C. Wainwright and Jones are lead managers, with Maxim Group and Lake Street as co-managers. RZLT shares stood at $3.65 at Friday's close.
Tumor Results Remain Preliminary
Rezolute reported Friday that its late-stage tumor-hyperinsulinism study met its main goal on preliminary results. Thirteen participants met the response threshold—a reduction of at least 50% in the rate of intravenous glucose needed—with 12 stopping intravenous glucose entirely.
The study enrolled 16 participants and has no placebo comparison. Three participants were still in the pivotal treatment period, including two who had not met the response threshold. One participant who left for home hospice died from cancer progression and was counted as a non-responder.
The company reported no drug-related adverse events or other safety findings attributed to ersodetug. The preliminary efficacy findings may change when the study is complete.
Preparation Before Approval
Ersodetug is an antibody given intravenously that acts on the insulin receptor. Rezolute is studying it for both tumor-related hyperinsulinism and congenital hyperinsulinism, which affects children. The company has no approved products and supplies the candidate through an expanded access program to patients unable to join a trial.
The congenital study missed its main and key secondary goals in December 2025. After reviewing additional data, the FDA encouraged Rezolute to seek a meeting before submitting an approval application, while explicitly making no judgment about approvability.
Research and development spending was about $53.8 million for the fiscal year ended June 30, 2026. The offering's commercialization preparation therefore accompanies a drug program still working toward regulatory review.
Rezolute expects completed tumor-study results, including statistical analysis, by mid-December 2026 and FDA discussions in the first quarter of 2027.
Sources
- Form 424B5 — Rezolute, Inc. (RZLT) — SEC EDGAR
- Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization — Yahoo Finance
- Rezolute Prices $100M Offering at $3.87 Per Share — kalkine.com
- Rezolute stock rises on positive Phase 3 upLIFT trial results By Investing.com — investing.com
- Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Markets Insider — Business Insider
- Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - BioSpace — biospace.com